Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by 2O2Ovisionon Mar 08, 2024 7:18am
176 Views
Post# 35922189

Options at FY2023

Options at FY2023Insiders haven't filed with the canadian securities in quite some time so we don't know who exercsied options (other than Andrew before he left) but the financials do shed some light on the subject. ONC booked proceeds of $781K from 450,391 excercised options in 2023. Insider ownership used to be around 850,000 shares at the last Sedi reporting date so we could be looking at roughly a 50% increase in ownership in December. Nothing huge but again we don't know what is going on until they file with Sedi. There were 480,000 options at $1.45 expiring in December so we can assume many were exercised, and the roughly 300,000 shares out of the money were let go. Some day we'll know wha'ts going on. Cheers.

<< Previous
Bullboard Posts
Next >>